The cost-effectiveness of new first-line therapies approved in advanced hepatocellular carcinoma

The introduction of targeted agents (lenvatinib) and immune-based therapies (atezolizumab in combination with bevacizumab) for first-line advanced hepatocellular carcinoma provided new therapeutic options. The aim of this paper was to assess the cost-effectiveness of lenvatinib and the combination o...

Full description

Saved in:
Bibliographic Details
Published in:Journal of oncology pharmacy practice 2022-03, Vol.28 (2), p.434-437
Main Authors: Giuliani, Jacopo, Mantoan, Beatrice, Bonetti, Andrea
Format: Article
Language:English
Subjects:
Antineoplastic Agents - therapeutic use
Bevacizumab
Bevacizumab - therapeutic use
Carcinoma, Hepatocellular - drug therapy
Clinical trials
Cost analysis
Cost-Benefit Analysis
Hepatocellular carcinoma
Humans
Immunosuppressive agents
Liver cancer
Liver Neoplasms - drug therapy
Survival
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The introduction of targeted agents (lenvatinib) and immune-based therapies (atezolizumab in combination with bevacizumab) for first-line advanced hepatocellular carcinoma provided new therapeutic options. The aim of this paper was to assess the cost-effectiveness of lenvatinib and the combination of atezolizumab plus bevacizumab in first-line for advanced hepatocellular carcinoma. Pivotal phase III randomized controlled trials were considered. Incremental cost-effectiveness ratio was calculated as the ratio between the difference of the costs in the intervention and in the control groups (pharmacy costs) and the difference between the effect in the intervention and in the control groups (progression free survival). One thousand four hundred and fifty five patients were included. The lowest cost for month of progression free survival-gain was associated with lenvatinib, with 139.24 € per month progression free survival-gained. Combining pharmacological costs of drugs with the measure of efficacy represented by progression free survival, lenvatinib is a cost-effective treatment in first-line for advanced hepatocellular carcinoma.
ISSN:1078-1552
1477-092X
DOI:10.1177/10781552211045013